- Report
- March 2025
- 175 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- August 2022
- 115 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2732EUR$3,000USD£2,349GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£392GBP
Votrient is a type of drug used to treat kidney cancer. It is a targeted therapy, meaning it works by targeting specific molecules involved in the growth and spread of cancer cells. Votrient works by blocking the action of certain proteins that help cancer cells grow and divide. It is used to treat advanced kidney cancer, and is often used in combination with other treatments such as chemotherapy and radiation therapy. Votrient is also used to treat other types of cancer, such as ovarian cancer and non-small cell lung cancer.
Votrient is a relatively new drug, and is still in the early stages of development. It is not yet widely available, and is only approved for use in certain countries. However, it is gaining popularity as a treatment for kidney cancer, and is being studied for use in other types of cancer.
Some companies in the Votrient market include Novartis, Pfizer, and AstraZeneca. These companies are researching and developing Votrient for use in treating kidney cancer and other types of cancer. Show Less Read more